curaleaf
curaleaf · page 2
- Medical Cannabis
Curaleaf Laboratories and Herdade das Barrocas (HDB) Announce Strategic Partnership to Reintroduce HDB Products to the UK Medical Cannabis Market
Curaleaf Laboratories, one of the UK’s leading manufacturers and distributors of EU-GMP medical cannabis products and Herdade das Barrocas (HDB), a Portuguese cultivator known for its cannabis genetics and cultivation expertise, are pleased to announce a new manufacturing and supply partnership that will see HDB products reintroduced to healthcare professionals and patients across the United…
- Investment & Finance
Listed: Cannabis Finally Cracks America’s Major Exchanges
Cannabis stocks have, for the last five years or so, represented one of, if not the worst-performing, niche categories on any exchange.
- Investment & Finance
Cannabis at an Inflexion Point: A Structural Repricing Ahead
Having spent over 30 years in advisory roles in financial markets prior to entering the cannabinoid industry, I lived through many hyperbolic boom/bust market cycles.
- M&A Activity
Curaleaf Completes Full Acquisition of Germany’s Four 20 Pharma
Curaleaf Holdings has completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH, making the Paderborn-based medical cannabis producer and distributor a wholly owned subsidiary of the international cannabis giant.
- M&A Activity
Has Rescheduling Accelerated the Cannabis M&A Wave?
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators.
- Policy & Regulation
The US Officially Reschedules Cannabis, Partly….
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
- Investment & Finance
Federal Agencies Reportedly Told to Prep for Imminent Cannabis Rescheduling Announcement
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
- Industry Trends
Rescheduling Stalemate Leaves MSOs Facing a Billion Dollar Tax Reckoning
The Trump administration’s continued inaction on its promise to push ahead with the highly anticipated cannabis rescheduling project is now presenting some real-world issues for many of the sector’s largest players.
- Industry Trends
What Is Really Going on in the UK’s Medical Cannabis Market? (New 2025 Data Analysis)
The UK’s medical cannabis industry has nearly tripled in size since 2022, according to new Freedom of Information data offering the most comprehensive look into what is being prescribed in the UK to date.
- CBD Market
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to authorise insurance coverage for CBD products under certain Medicare programs, even as the same products face an existential threat from recently passed federal legislation.
- Events
Business of Cannabis: New York 2025 – Key Takeaways
Business of Cannabis: New York 2025 arrived at a crucial moment not just for the local cannabis industry, but for the entire state.
- Investment & Finance
Trump Sends Cannabis Stocks Surging, Cantourage Brings in Investor Relations Help, & Mamedica Secures £4.5m
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after US President Donald Trump shared a video apparently endorsing the use of CBD for senior healthcare.
